Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gadopentetate Dimeglumine→

Gadopentetate Dimeglumine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
86050-77-3
Molecular formula
C28H54GdN5O20
Molecular weight
938 g/mol
Drug class
Gadolinium-based paramagnetic magnetic-resonance imaging (MRI) contrast agent
Mechanism of action
A gadolinium-DTPA chelate that produces a paramagnetic effect in a magnetic field, shortening the T1 and T2 relaxation times of nearby water protons and enhancing MRI signal.
Indications / reported uses
  • Contrast enhancement during MRI of intracranial lesions with abnormal vascularity or abnormalities of the blood-brain barrier, as described in product information.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gadopentetate-dimeglumine · https://www.ncbi.nlm.nih.gov/books/NBK559370/table/ch2.tab1/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gadopentetate Dimeglumine Environmental Risk Assessment (ERA) (the Gadopentetate Dimeglumine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.